ClinicalTrials.gg
CompletedNCT01422382Updated Jul 13, 2012Results posted

Drug-Drug Interaction of Cardizem LA (Diltiazem Hydrochloride) on Pitavastatin

A Phase 4 interventional study of Pitavastatin (NK-104) and Diltiazem (Cardizem LA) 240 mg QD in Healthy, sponsored by Kowa Research Institute, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-07-13.

Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a Phase 4, single-center, open-label, fixed-sequence, multiple-dose, 2-way drug-drug interaction study.

Read the detailed description

Each subject will qualify for entry into the study not more than 30 days prior to admission into the clinical unit. Subjects will check into the clinical unit on Day -1 for baseline assessments. During the treatment period, each subject will receive a once-daily dose of pitavastatin 4 mg on Days 1 through 5 and on Days 11 through 15 and a once-daily dose of diltiazem 240 mg on Days 6 through 15. Subjects will fast overnight for at least 8 hours before dosing and will remain fasted until 4 hours after dosing on the morning of Days 5, 10, and 15.

02

Conditions studied

  • Healthy

Keywords

  • Healthy Volunteers
03

In context

Lead sponsor

Kowa Research Institute, Inc. is the lead sponsor of 47 studies on the registry; 1 is open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 9 (45%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult male or female volunteer aged 18 to 45 years, inclusive.
  • Subject has a of 18 to 30 kg/m2, inclusive.
  • Subject has normal hematology, serum chemistry, and urinalysis test results.
  • Subject is able and willing to abstain from alcohol, grapefruit-containing foods or beverages, caffeine, or caffeine-containing products, St John's wort, and herbal supplements for 4 days before Day 1 and until after completion of this study.
  • Subject is a nonsmoker or has quit smoking at least 6 months before the first dose of study drug and until after study completion.

Exclusion criteria

Exclusion Criteria:

  • Subject has had any surgery of the gastrointestinal tract likely to affect drug absorption, distribution, metabolism, or excretion.
  • Subject has had a previous allergy or intolerance to treatment with pitavastatin, diltiazem, or any drugs in these classes.
  • Subject has a history of drug or alcohol abuse.
  • Subject has had a illness within 4 weeks before the first dose of study drug.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    All Subjects

    There was 1 treatment period, with each subject receiving a once-daily dose of pitavastatin 4 mg on Days 1 through 5 and on Days 11 through 15 and a once-daily dose of diltiazem 240 mg on Days 6 through 15

    Drug: Pitavastatin (NK-104) · Drug: Diltiazem (Cardizem LA) 240 mg QD

Interventions

06

What researchers measure

Primary outcomes

  1. NK-104 AUC

    Time frame: 15 Days

Secondary outcomes

  1. Number of Participants With at Least One Adverse Event.

    Time frame: 24 Days

07

Results

Posted Apr 12, 2012

Participant flow

1st Subject Enrolled 05 May 2011, Last Subject Completed 12 July 2011 at PPD Inc. 7551 Metro Center Drive Suite 200 Austin, TX 78744

NK-104 4mg Once Daily (QD)
Participant flow — NK-104 4mg Once Daily (QD)
MilestoneAll Subjects
Started28
Completed28
Not completed0
Diltiazem 240 mg QD
Participant flow — Diltiazem 240 mg QD
MilestoneAll Subjects
Started28
Completed28
Not completed0
NK-104 4mg QD and Diltiazem 240 mg QD
Participant flow — NK-104 4mg QD and Diltiazem 240 mg QD
MilestoneAll Subjects
Started28
Completed27
Not completed1
Withdrew: Personal reasons1

Outcome measures

PrimaryNK-104 AUC
Time frame:
15 Days
Reported as:
Mean · ng * h/mL
NK-104 AUC
ng * h/mLAll Subjects
NK-104 AUC208.92 ± 86.54
SecondaryNumber of Participants With at Least One Adverse Event.
Time frame:
24 Days
Reported as:
Number · Participants
Number of Participants With at Least One Adverse Event.
ParticipantsAll Subjects
Number of Participants With at Least One Adverse Event.12

Adverse events

Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Subjects—0/28 (0%)12/28 (42.9%)
Most frequent other events
Most frequent other events
EventAll Subjects
HeadacheNervous system disorders5/28
PresyncopeNervous system disorders3/28
NasopharyngitisInfections and infestations2/28
CoughRespiratory, thoracic and mediastinal disorders2/28

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)All Subjects
<=18 years0
Between 18 and 65 years28
>=65 years0
Age Continuous
Age Continuous(years)All Subjects
Mean29.2 ± 7.63
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects
Female11
Male17
Region of Enrollment
Region of Enrollment(participants)All Subjects
United States28
08

Study locations

1 site
  • Austin, Texas, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Jun 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2011
First posted
Aug 24, 2011
Start
May 2011
Primary completionActual
Jun 2011
CompletionActual
Jul 2011
Results first posted
Apr 12, 2012
Last update
Jul 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01422382
Responsible party
Sponsor
First posted
Aug 24, 2011
Start date
May 2011
Primary completion
Jun 2011
Completion
Jul 2011
Results posted
Apr 12, 2012
Last update
Jul 13, 2012

Study contacts

Roger Morgan, MD, FACS
study director · Kowa Research Institute, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pitavastatin · Diltiazem

Start the discussion